U.S. markets open in 1 hour 11 minutes
  • S&P Futures

    3,718.75
    +48.75 (+1.33%)
     
  • Dow Futures

    29,656.00
    +313.00 (+1.07%)
     
  • Nasdaq Futures

    11,494.50
    +178.25 (+1.58%)
     
  • Russell 2000 Futures

    1,688.20
    +25.70 (+1.55%)
     
  • Crude Oil

    77.78
    +1.07 (+1.39%)
     
  • Gold

    1,644.20
    +10.80 (+0.66%)
     
  • Silver

    18.68
    +0.20 (+1.11%)
     
  • EUR/USD

    0.9641
    +0.0030 (+0.31%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    30.99
    +1.07 (+3.58%)
     
  • GBP/USD

    1.0802
    +0.0119 (+1.11%)
     
  • USD/JPY

    144.4270
    -0.2530 (-0.17%)
     
  • BTC-USD

    20,291.92
    +1,424.33 (+7.55%)
     
  • CMC Crypto 200

    463.54
    +30.44 (+7.03%)
     
  • FTSE 100

    7,039.55
    +18.60 (+0.26%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Guardion Health Sciences Launches New Viactiv® Omega BOOST™ Passion Fruit Flavored Gel Bites

·2 min read
Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc.

New Omega BOOST™ Gel Bites Provide 10x More Omega-3 Than Leading Gummies

Individually Packaged in Blisterpacks to Ensure Freshness and Portability

Omega BOOST™ is the First New Viactiv® Product Launch Since Guardion Acquired the Brand in June 2021

HOUSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, announced the launch of Viactiv Omega BOOST gel bites, the Company’s first expansion of the Viactiv brand since the Company acquired it in June 2021. The 1,200 mg Omega-3 gel bites are designed to provide total body support, including cardiovascular, brain, joint and eye health.

The new dosage form is able to provide the potency of large, hard-to-swallow soft gels, in a great tasting chewable format that has ten times more Omega-3 than the leading fish oil gummies. The gel bite dosage form has been shown to have better absorption and fewer digestive issues than regular soft gel formulas, as well as no unpleasant fishy aftertaste and no sugar, which can all be associated with certain other Omega-3 products.

“Our new Omega Boost product is an exciting addition to our Viactiv line as it introduces a new dosage form that addresses a gap in the Omega-3 market – clinically proven levels of Omega-3 in an easy to take, great tasting product that you will look forward to taking every day,” commented Bret Scholtes, Guardion’s Chief Executive Officer. “Further, a study of consumer use of dietary supplements has shown strong overlap between calcium users and those who use Omega-3 supplements. We are excited to be able to offer these supportive nutrients under the same trustworthy Viactiv brand and look forward to continuing to be a reliable and sought-after resource for the nutritional supplement needs of our customers.”

Omega BOOST™ will be available for pre-order at www.viactiv.com beginning February 15, 2022.

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition company. Guardion’s portfolio of science-based, clinically supported nutrition, medical foods, and supplement products support healthcare professionals, their patients, and consumers in achieving health goals.. The Company’s combination of expertise and scientifically supported products is the foundation of Guardion’s growing position within the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U. S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but are not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of a new management team, the integration of one or more acquisitions and targets, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
CORE IR
Scott Arnold
516-222-2560
scotta@coreir.com

Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com